Physician profile
John Porter
NPI 1205182508
$5,838.96
in general payments reported to CMS, 2019-2025
32 companies · $649 in 2025
The $649 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $1,136 · 2021: $789 · 2022: $686 · 2023: $889 · 2024: $896 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,340.09 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,169.36 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $682.36 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $602.56 | 2019-2022 | |
| Novo Nordisk INC | $542.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $373.26 | 2019-2025 | |
| Astellas Pharma US INC | $325.90 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $301.64 | 2019-2025 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.53 | 2019-2025 | Jardiance |
| Abbvie INC. | $180.48 | 2021-2025 | |
| Amgen INC. | $177.62 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $162.64 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $157.30 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $149.76 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $120.36 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $102.23 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.19 | 2022-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $99.19 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $90.82 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $83.30 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $44.85 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $20.48 | 2023 | Inpefa |
| Axsome Therapeutics, INC. | $19.92 | 2025 | Auvelity |
| Horizon Therapeutics Plc | $19.61 | 2023 | Krystexxa |
| Hologic Sales and Service, LLC | $17.80 | 2021 | |
| Allergan, INC. | $17.67 | 2020 | |
| Merck Sharp & Dohme LLC | $17.06 | 2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $16.93 | 2020 | |
| Bioventus LLC | $16.59 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.84 | 2021 | |
| Depuy Synthes Sales INC. | $12.75 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.